Engineering innate immune cells for cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Innate immune cells, including natural killer (NK) cells, macrophages, and gamma delta (γδ) T cells, are emerging as key players in cancer immunotherapy.
• These cells offer advantages over conventional T cell therapies, such as inherent antitumor activity and antigen-independent targeting.

Purpose of the Study:

• To review engineering strategies aimed at enhancing the anticancer potential of innate immune cells.
• To discuss challenges and insights from preclinical and clinical studies involving engineered innate immune cells.
• To propose future strategies for advancing innate immune cell engineering in cancer therapy.

Main Methods:

• Review of existing literature on innate immune cell engineering for cancer immunotherapy.
• Analysis of preclinical and clinical data.
• Identification and discussion of engineering strategies and associated challenges for NK cells, macrophages, and γδ T cells.

Main Results:

• Innate immune cells possess inherent antitumor properties and can target various cancers without prior sensitization.
• Engineering approaches are being developed to augment the efficacy and specificity of these cells.
• Challenges remain in optimizing cell persistence, trafficking, and overcoming the tumor microenvironment.

Conclusions:

• Engineered innate immune cells represent a powerful and versatile platform for cancer immunotherapy.
• Addressing current challenges through innovative engineering strategies will be crucial for clinical translation.
• Further research and clinical validation are needed to fully realize the therapeutic potential of innate immune cell engineering.